MK-677 Plus Alendronate: Combining Bone Building With Bone Protection for Osteoporosis
Combining oral MK-677 (which builds bone) with alendronate (which prevents bone breakdown) maintained higher bone formation than alendronate alone in postmenopausal women, supporting a dual approach to osteoporosis.
Quick Facts
What This Study Found
MK-677 combined with alendronate maintained higher bone formation markers than alendronate alone over 12 months in postmenopausal women, demonstrating complementary mechanisms: IGF-1-stimulated bone building plus anti-resorptive bone protection.
Key Numbers
How They Did This
Randomized, double-blind, placebo-controlled study. Postmenopausal women received: MK-677 25mg/day, alendronate 10mg/day, combination, or placebo for 12 months. Bone turnover markers, BMD, IGF-1 measured.
Why This Research Matters
Current osteoporosis drugs are mainly anti-resorptive (they slow bone loss). Adding a bone-building agent could produce superior outcomes. This study demonstrates the principle with an oral GH secretagogue.
The Bigger Picture
Osteoporosis treatment may need both offense (building bone) and defense (preventing breakdown). MK-677's bone-building effect via IGF-1 complements alendronate's bone-protecting effect for a dual-mechanism approach.
What This Study Doesn't Tell Us
Bone turnover markers are surrogates — actual fracture prevention not assessed. 12 months may not predict long-term bone density outcomes. Sample size details not in abstract.
Questions This Raises
- ?Does the dual approach reduce fracture risk more than alendronate alone?
- ?What is the optimal duration of combined therapy?
- ?Could MK-677 replace teriparatide as the bone-building partner?
Trust & Context
- Key Stat:
- Build + protect MK-677 sustained bone formation that alendronate alone suppressed, creating a dual-mechanism approach: build new bone while preventing old bone loss
- Evidence Grade:
- Moderate evidence from a well-designed 12-month RCT with bone turnover markers, limited by surrogate endpoints rather than fracture data.
- Study Age:
- Published in 2001. The concept of combining anabolic and anti-resorptive therapies for osteoporosis has been validated with other drugs (romosozumab + denosumab).
- Original Title:
- Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
- Published In:
- The Journal of clinical endocrinology and metabolism, 86(3), 1116-25 (2001)
- Authors:
- Murphy, M G(3), Weiss, S, McClung, M, Schnitzer, T, Cerchio, K, Connor, J, Krupa, D, Gertz, B J
- Database ID:
- RPEP-00682
Evidence Hierarchy
Frequently Asked Questions
Why combine two osteoporosis approaches?
Alendronate prevents bone breakdown but also slows bone building. Adding MK-677 stimulates new bone formation through growth hormone and IGF-1, counteracting alendronate's limitation. Together: build AND protect.
Is this better than alendronate alone?
Bone formation markers stayed higher with the combination. Whether this translates to fewer fractures needs further study, but the principle of combining build-and-protect strategies is now a leading approach in severe osteoporosis.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00682APA
Murphy, M G; Weiss, S; McClung, M; Schnitzer, T; Cerchio, K; Connor, J; Krupa, D; Gertz, B J. (2001). Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.. The Journal of clinical endocrinology and metabolism, 86(3), 1116-25.
MLA
Murphy, M G, et al. "Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.." The Journal of clinical endocrinology and metabolism, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Effect of alendronate and MK-677 (a growth hormone secretago..." RPEP-00682. Retrieved from https://rethinkpeptides.com/research/murphy-2001-effect-of-alendronate-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.